Ekologiya cheloveka (Human Ecology)Ekologiya cheloveka (Human Ecology)1728-08692949-1444Eco-Vector10905510.17816/humeco109055Research ArticleHormonal and metabolic features of puberty in adolescents with ultrasound signs of fatty hepatosis (on the example of Arkhangelsk)MalyavskayaSvetlana I.<p>MD, Dr. Sci. (Med.), professor</p>malyavskaya@yandex.ruhttps://orcid.org/0000-0003-2521-0824LebedevAndrey V.<p>MD, Cand. Sci. (Med.), associate professor</p>andruleb@yandex.ruhttps://orcid.org/0000-0003-1865-6748KostrovaGalina N.<p>MD, Cand. Sci. (Med.), associate professor</p>kostrovagn@yandex.ruhttps://orcid.org/0000-0002-3132-6439Northern State Medical University2912202229118078151107202231102022Copyright © 2022, Eco-Vector2022<p><strong><em>AIM:</em></strong> To establish the nature of hormonal and metabolic disorders and the relationship of atherogenic risk factors in puberty in adolescents with ultrasound signs of fatty hepatosis.</p>
<p><strong><em>METHODS: </em></strong>A sample of 120 adolescents aged 1217 years from Arkhangelsk having instrumental signs of fatty hepatosis were examined for indicators of peroxidation, chronic inflammation and insulin resistance. A group of 219 adolescents from Arkhangelsk who did not have acute and chronic diseases at the time of examination were used as a comparison group.</p>
<p><strong><em>RESULTS: </em></strong>The results showed higher mean values of total C-reactive protein (2.76 mg/ml), lipid peroxidation (531.28 mmol/l), waist circumference (72.15 cm), body mass index (25.70 kg/m<sup>2</sup>), uric acid (0.29 mmol/l), HOMA index (2.24 IU), insulin (11.92 uIU/ml), triglycerides (0.91 mmol/l), and low-density lipoprotein cholesterol (2.20 mmol/l) in the group of adolescents with fatty hepatosis than in the comparison group (0.77 mg/ml, <em>p</em> 0.001; 371.19 mmol/l, <em>p</em>=0.027; 58.19 cm, <em>p</em> 0.001; 25.70 kg/m<sup>2</sup>, <em>p</em> 0.001; 0.25 mmol/l, <em>p</em> 0.001; 1.01 IU, <em>p</em> 0.001; 5.90 uIU/ml, <em>p</em> 0.001; 0.69 mmol/l, <em>p</em> 0.001; 2.06 mmol/l, <em>p</em>=0.025, respectively).</p>
<p><strong><em>CONCLUSION: </em></strong>These results confirm that the pathogenetic components of non-alcoholic fatty liver disease (insulin resistance, accompanied by hyperinsulinemia against the background of abdominal fat deposition, activation of lipid peroxidation, atherogenic dyslipidemia, hyperuricemia, and chronic inflammation) should be considered in adolescence in the prevention, diagnosis, monitoring, and treatment of non-alcoholic fatty liver disease.</p>metabolic syndromenon-alcoholic fatty liver diseasefatty hepatosisadolescentsinsulin resistancelipid peroxidationdyslipidemiaметаболический синдромнеалкогольная жировая болезнь печенижировой гепатозподросткиинсулинорезистентностьперекисное окисление липидовдислипидемии[Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi: 10.1038/nrgastro.2017.109][Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. doi: 10.1002/hep.29466][Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology. 2018;67(5):1726–1736. doi: 10.1002/hep.29546][Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–e185. doi: 10.1161/ATV.0000000000000153][Lazebnik LB, Golovanova EV, Turkina SV, et al. Non-alcoholic fatty liver disease in adults: clinic, diagnosis, treatment. Recommendations for therapists, the third version. Experimental and clinical gastroenterology journal. 2021;(1):4–52. (In Russ). doi: 10.31146/1682-8658-ecg-185-1-4-52][Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–2023. doi: 10.1002/hep.25762][Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344. doi: 10.1038/nrgastro.2013.41][Hosseini S-M, Mousavi S, Poursafa P, Kelishadi R. Risk score model for predicting sonographic non-alcoholic fatty liver disease in children and adolescents. Iran J Pediatr. 2011;21(2):181–187.][Fu Ch-Ch, Chen M-Ch, Li Y-M, et al. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents. Ann Acad Med Singapore. 2009;38(1):15–17.][Novikovа VP, Aleshinа EI, Gurovа MM, editors. Nealkogol'naja bolezn' pecheni v detskom vozraste. Moscow: GJeOTAR-Media, 2016. 176 p. (In Russ).][Kahen T, Schwimmer J, Lavine J, et al. Population prevalence of pediatric fatty liver disease. Gastroenterol. 2004;126:A753–A754.][Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: Clinical Guidelines of the Russian Scientific Liver Society and the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24–42. (In Russ).][Schwimmer JB, Deutsch R, Rauch JB, et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoolic fatty liver disease. J Pediatr. 2003;143(4):500–505. doi: 10.1067/S0022-3476(03)00325-1][Sinitsin PA, Sherbakova MYu, Larionova VI, Petryaikina EE. Metabolic syndrome in children. Pediatrics. Journal named after G.N. Speransky. 2008;87(5):116–119. (In Russ).][Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–334. doi: 10.1097/MPG.0000000000001482][Novikova VP, Aleshina EI, Leonova IA, et al. Kliniko-immunologicheskie i metabolicheskie osobennosti detej s morbidnym ozhireniem. Voprosy detskoj dietologii. 2017;15(1):61–62. (In Russ).][Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi: 10.1016/j.metabol.2015.12.012][Aver'janov AP. Ozhirenie u detej i podrostkov: kliniko-metabolicheskie osobennosti, lechenie, prognoz i profilaktika oslozhnenij [dissertation]. Saratov; 2009. Available from: https://www.dissercat.com/content/ozhirenie-u-detei-i-podrostkov-kliniko-metabolicheskie-osobennosti-lechenie-prognoz-i-profil/read (In Russ).][Krivoshhjokov SG. Psihofiziologicheskie mehanizmy adaptacii i dezadaptacii na Severe. In: Materialy 13 Mezhdunarodnogo Kongressa po pripoljarnoj medicine. 2006 Jun 12–16; Novosibirsk; 2022. P. 6. (In Russ).][Sovershaeva SL, Danilova RI, Degteva GN, Budjak VP. Adaptacija cheloveka v vysokih shirotah. Morskoj medicinskij zhurnal. 1996;(4):15–17. (In Russ).][Baranov AA, Kuchma VR, Skoblina NA, et al. The main mechanisms of morphofunctional development of children and adolescents in modern conditions. Annals of the Russian Academy of Medical Sciences. 2012;67(12):35–40. (In Russ). doi: 10.15690/vramn.v67i12.479][Bezrukih MM, Son'kin VD, Farber DA. Vozrastnaja fiziologija (fiziologija razvitija rebenka). Moscow: Akademija; 2002. 416 p. (In Russ).][Gurkin JuA. Ginekologija podrostkov. Saint-Petersburg: IKF «Foliant»; 2000. 574 p. (In Russ).][Patton HM, Sirlin S, Behling C, et al. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr. 2006;43(4):413–427. doi: 10.1097/01.mpg.0000239995.58388.56][European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004][Smirnov VV, Nakula AA. Ozhirenie v detskom i pubertatnom periode: jetiopatogenez, oslozhnenija, lechenie. Lechashhij vrach. 2015;(10):61. (In Russ).][Bueverov OA. Oxidative stress and its role in liver damage. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2002;12(4):21–22. (In Russ).][Malyavskaya SI, Lebedev AV. The characteristics of dyslipidemia in children and adolescents of the city of Arkhangelsk. Disease Treatment and Prevention. 2014;1:36–41. (In Russ).][Malyavskaya SI, Lebedev AV. The relevance of metabolic phenotypes of obesity in childhood and adolescence. Almanac of Clinical Medicine. 2015;(42):38–45. (In Russ). doi: 10.18786/2072-0505-2015-42-38-45]